Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in adults (second to the flu) with no specific prevention and treatment options. While RSV can infect anyone, for some people, especially babies, older adults, and those with heart or lung problems or weakened immune systems, symptoms can be more severe. Around the world, there is an urgent need for a vaccine that can prevent RSV. That’s why Pfizer is conducting the C3671006 investigational RSV vaccine and flu vaccine study. Pfizer is committed to developing a safe and effective vaccine to prevent RSV or make it less severe, with a special focus on protecting infants and older adults.
We are enrolling healthy males and females who (among other things):